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Abstract
Aims We aimed to determine whether in children with dilated cardiomyopathy repeated measurement of known risk factors
for death or heart transplantation (HTx) during disease progression can identify children at the highest risk for adverse
outcome.
Methods and results Of 137 children we included in a prospective cohort, 36 (26%) reached the study endpoint (SE:
all-cause death or HTx), 15 (11%) died at a median of 0.09 years [inter-quartile range (IQR) 0.03–0.7] after diagnosis,
and 21 (15%) underwent HTx at a median of 2.9 years [IQR 0.8–6.1] after diagnosis. Median follow-up was 2.1 years [IQR
0.8–4.3]. Twenty-three children recovered at a median of 0.6 years [IQR 0.5–1.4] after diagnosis, and 78 children had ongoing
disease at the end of the study. Children who reached the SE could be distinguished from those who did not, based on the
temporal evolution of four risk factors: stunting of length growth (0.42 vs. 0.02 length Z-score per year, P < 0.001), less
decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) (0.26 vs. 1.06 2log pg/mL/year, P < 0.01), no decrease
in left ventricular internal diastolic dimension (LVIDd; 0.24 vs. 0.60 Boston Z-score per year, P < 0.01), and increase in New
York University Pediatric Heart Failure Index (NYU PHFI; 0.49 vs. 1.16 per year, P < 0.001). When we compared children who
reached the SE with those with ongoing disease (leaving out the children who recovered), we found similar results, although
the effects were smaller. In univariate analysis, NT-proBNP, length Z-score, LVIDd Z-score, global longitudinal strain (%), NYU
PHFI, and age >6 years at presentation (all P < 0.001) were predictive of adverse outcome. In multivariate analysis,
NT-proBNP appeared the only independent predictor for adverse outcome, a two-fold higher NT-proBNP was associated with
a 2.8 times higher risk of the SE (hazard ratio 2.78, 95% confidence interval 1.81–3.94, P < 0.001).
Conclusions The evolution over time of NT-proBNP, LVIDd, length growth, and NYU PHFI identified a subgroup of children
with dilated cardiomyopathy at high risk for adverse outcome. In this sample, with a limited number of endpoints,
NT-proBNP was the strongest independent predictor for adverse outcome.
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Introduction
In children with dilated cardiomyopathy (DCM), up to 50% of
children die or undergo heart transplantation (HTx) within
5 years after diagnosis.1–3 DCM is the most common indica-
tion for HTx in children. Worldwide, several large paediatric
DCM cohorts have reported risk factors at presentation for
adverse outcome and identified older age (>6 years), worse
left ventricular (LV) fractional shortening, congestive
heart failure at presentation, idiopathic DCM, and higher
N-terminal pro-B-type natriuretic peptide (NT-proBNP) as risk
factors for death or HTx.1–4 Previously, we reported on similar
risk factors at presentation.5 Also, we demonstrated that
follow-up parameters like NT-proBNP, 6 min walking dis-
tance, and longitudinal strain, all obtained relatively early af-
ter presentation in cross-sections of our national cohort
of children with DCM, contained important prognostic
information.5–8 However, changes in these risk factors during
the further course of the disease, alone or in concert, might
hold valuable prognostic information as well.2,6,9 This may
further pinpoint the group of children at the highest risk for
adverse outcome, which is essential as these are the patients
who should be monitored closely and, importantly, be listed
for HTx at a timely stage.
In this present study, we prospectively and repeatedly col-
lected a set of established clinical, laboratory, and echocar-
diographic risk factors for death and transplantation in a
national cohort of children with DCM. We explored the tem-




Data were collected in a multicentre, prospective study de-
sign. Patients from eight tertiary cardiac centres were in-
cluded from October 2010 to July 2017. We enrolled
children with prior (until 2010) or new diagnosis (from 2010
onward). As the purpose was to study primary cardiac disease
with impaired systolic function, DCM was defined as the pres-
ence of impaired systolic function based on echocardiogra-
phy: a fractional shortening ≤25% in combination with LV
end-diastolic dimension >+2 Z-score for body surface area.
Patients with congenital heart disease, neuromuscular dis-
ease, or systemic diseases that transiently impaired systolic
function were excluded. Data were collected during routine
outpatient clinic visits or coincided with hospital admissions.
In the first year after diagnosis, patients were evaluated 1–4
times per year, and 1–2 times per year thereafter, depending
on the frequency of outpatient visits. Subjects were followed
until death or HTx, until the age of 18 years, or until the last
outpatient visit within the study window. This study was ap-
proved by the Medical Ethical Committee of the Erasmus
MC (MEC 2014-062) and was performed in accordance with
the Declaration of Helsinki. All parents as well as children
≥12 years gave written informed consent.
Study variables
In this study, we focused on six known risk factors for adverse
outcome.
N-terminal pro-B-type natriuretic peptide
N-terminal pro-B-type natriuretic peptide values were mea-
sured using the Elecsys® assay in all participating centres.
New York University Pediatric Heart Failure Index
New York University Pediatric Heart Failure Index (NYU PHFI)
is a paediatric heart failure score that quantifies the degree of
heart failure in terms of symptoms and medication use and
ranges from 0 to 30 points.10 The treating paediatric cardiol-
ogist completed the NYU PHFI.
Length Z-score
Length was normalized to Z-scores using Growth Analyser©,
which is based on reference values for Dutch children.11
Left ventricular internal diastolic diameter
A standardized echocardiogram was performed, and data
were analysed using the mean value of three consecutive car-
diac cycles. Echocardiograms were analysed by study person-
nel who were blinded to the patient’s name, previous
echocardiograms, and other study results. The left ventricular
internal diastolic diameter (LVIDd) was normalized to a
Boston Z-score for body surface area, age, and gender.12
Global longitudinal strain
Global longitudinal strain (GLS) was calculated as the mean of
the peak strain of all LV segments in a longitudinal
six-segment model as previously described.8
Six minute walking distance
The distance walked within 6 min on a 8 m track was re-
corded and expressed as percentage of predicted (6MWD%)
according to Geiger et al., accounting for height, gender,
and age.7,13
The clinical team was blinded to the results of the 6MWD%
and GLS, and the other study variables were readily available.
In addition to the previously mentioned study variables, DCM
aetiology, age at diagnosis, weight (normalized to Z-score),
and current heart failure medications were collected as well.
Genetic aetiology was defined as the presence of a mutation
in a known pathogenic DCM gene. Myocarditis was accepted
as aetiology if diagnosis was definite or probable.14
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Study endpoint
The study endpoint (SE) was all-cause death or HTx. We also
recorded the status of the surviving patients at the end of the
study period: ongoing disease or recovered. Recovery was
defined as two consecutive echocardiograms obtained with
at least 1 month interval, with normalized LVIDd and frac-
tional shortening, and the date of the first normalized echo-
cardiogram was considered as date of recovery.
Statistical analysis
Continuous baseline variables with normal distribution are
described as mean (standard deviation) or as median [inter-
quartile range (IQR)] otherwise. Categorical baseline variables
are described as numbers and percentages. Differences in
characteristics between patients with and without the SE
were compared by Student’s t-tests (normal distribution) or
Mann–Whitney U tests. We applied the method of Kaplan–
Meier to study survival and transplant-free survival.
To explore the temporal evolution of the study variables,
while accounting for the correlation between measurements
in the individual patient, we applied a linear mixed-effects
model (LMEM) for longitudinal data. To study the association
between study variables (repeatedly measured) and the SE,
we subsequently combined the LMEM with a Cox propor-
tional hazard regression model in a so-called joint model
(JM). In the multivariable joint model, we included stepwise
the studied risk factors starting with NT-proBNP based on
the fact that NT-proBNP has shown to be a robust marker
for outcome. Results of LMEM analyses are reported as mean
values [95% confidence intervals (CIs)], whereas results of the
JM analyses are reported as hazard ratio and 95% CI.
To further characterize the children who reached the SE, we
compared them with the patients who remained endpoint
free but still had ongoing disease at the end of the follow-up
period, thus leaving out the children who recovered. Temporal
evolution of the study variables was studied, in the same way
as described previously. The level of statistical significance for
all analyses was set at P = 0.05. Analyses were performed
using IBM SPSS Statistics 24 (IBM, New York, NY, USA) and R
statistical software Version 3.5.1 (free software, package
JMbayes, see https://www.r-project.org/foundation/).
Results
Patients and clinical outcome
A total of 137 children with DCM were included; three pa-
tients left the study early and were censored at their last
study visit. Of these 137 children, 96 were included directly
after diagnosis, whereas 41 children had a prior diagnosis.
Thirty-six children (26%) reached the SE, 15 children (11%)
died, and 21 children (15%) underwent transplantation.
Seventeen children reached an SE within 1 year after diagno-
sis (12 died and 5 underwent transplantation), and nine of
those 17 early endpoints were reached within 1 month after
diagnosis (seven children died and two underwent transplan-
tation). The majority of deaths (12 out of 15; 80%) occurred
within 1 year after diagnosis. Median time from diagnosis
to death was 1 month (0.09 years [IQR 0.03–0.7]), and me-
dian time to HTx was 2.9 years [IQR 0.8–6.1]. At some stage,
during the first year after inclusion, the majority of children
were on heart failure medication: 84% of children were on
an ACE inhibitor, 65% were on a beta-blocker, and 87% were
on one of both. Sixteen of 17 children who were not on oral
heart failure medication reached an SE before medication
could be started. All medications were up-titrated to the
maximum tolerated dose at the discretion of the treating
physician.
At the end of the study, after a median follow-up of
3.0 years [IQR 1.5–4.7], 23 children (24% of newly diagnosed
patients) had recovered and 78 children (57%) had ongoing
disease. Time from diagnosis to recovery was 0.6 years [IQR
0.5–1.4]. When comparing children who reached an SE and
those who did not, we found no important differences in pa-
tient and clinical characteristics (see Table 1).
In children who were included directly after diagnosis
(n = 96), 1 year survival was 88% (95% CI 83–95%) and 5 year
survival was 82% (95% CI 74–90%). The transplant-free sur-
vival was 82% (95% CI 74–89%) after 1 year and 72% (95%
CI 62–82%) after 5 years (Supporting Information, Figure S1).
In the children with a previous diagnosis (n = 41), 13 pa-
tients (32%) reached an SE, 2 children died, and 11 patients
underwent transplantation. Median time from diagnosis to
inclusion was 3.8 years [IQR 2.5–8.7], and median time from
diagnosis to SE was 6.0 years [IQR 3.1–9.7]. At the end of the
study, 28 patients had ongoing disease and no patient had
recovered.
Differences in risk factors, study endpoint vs. no
study endpoint
At the moment of first diagnosis, children who ultimately
reached the SE had an unfavourable clinical profile compared
with those who remained event-free. In particular, (mean)
NT-proBNP levels and NYU PHFI scores were higher, whereas
GLS and 6MWD% were lower (Table 2).
The temporal evolution of four risk factors was clearly dif-
ferent between children with and without the SE (Table 2 and
Figure 1). NT-proBNP levels, LVIDd, and NYU PHFI score
remained high in those who reached the SE, while
event-free children showed (steadily) decreasing values. Fur-
thermore, length growth was severely stunted in children
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with the SE, while a normal length growth was maintained
over time in their event-free counterparts.
Differences in risk factors, study endpoint vs.
ongoing disease
Comparable differences between patients with and without
SE were observed in a sensitivity analysis that excluded
the patients who recovered, although effect sizes were
smaller (Table 3 and Figure 2). Thus, in children with the
SE, the mean value at the time of diagnosis of NT-proBNP
and NYU PHFI were significantly higher, and GLS and
6MWD% were significantly lower. Furthermore, in children
with the SE, NT-proBNP, LVIDd, and NYU PHFI all remained
high, while in the children without the SE, all decreased over
time. Length Z-score indicated that in children who reached
an endpoint, length growth was severely stunted, while in
those with ongoing disease, growth was less severely
impaired.
Table 1 Patient and clinical characteristics at the time of diagnosis, comparing children who died or underwent transplantation with chil-
dren who survived without transplantation
Study endpoint N = 36 No study endpoint N = 101
Age (years) [IQR]a 5.3 [0.2–11.3] 0.9 [0.1–4.8]
<1 year, n (%) 14 (39) 50 (49)
1 to <6 years, n (%) 5 (14) 28 (28)
6 to <18 years, n (%) 17 (47) 23 (23)
Female, n (%)b 23 (64) 45 (45)
Time Dx to study inclusion (years) [IQR]a 0.01[0.0–2.5] 0.05 [0.0–2.3]
Time inclusion to last FU (years) [IQR]a 0.15 [0–1.7]* 3.0 [1.5–4.7]
Time diagnosis to last FU [IQR]a 1.3 [0.1–4.3]* 3.5 [2.0–6.1]
Primary diagnosis, n (%)
Idiopathic 16 (44) 51 (50)
Myocarditis 3 (8) 20 (20)
Familial 6 (17) 12 (12)
Inborn error of metabolism 2 (6) 2 (2)
Malformation syndrome 0 2 (2)
Anthracyclin related 1 (3) 7 (7)
Other 8 (22) 7 (7)
Weight for age, Z-score, mean (SD)c 0.6 (1.7) 0.8 (1.3)
Weight for height, Z-score, mean (SD) 0.4 (1.5) 0.4 (1.8)
Height for age, Z-score, mean (SD) 0.4 (1.4) 0.5 (1.5)
Shortening fraction (%) [IQR] 13 [9–16] 16 [12–20]
NT-proBNP (pg/mL) [IQR] 9922 [2592–25 974] 4180 [520–25 057]
Dx, diagnosis; FU, follow-up; IQR, inter-quartile range; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation.
Continuous variables as mean (SD) or median [IQR].
aMann–Whitney U test.
bχ2 test.
cWeight for age only in children under 15 months (n = 43).
*P < 0.05.
Table 2 Differences in risk factors between patients who reached the study endpoint of all-cause death or heart transplantation and
those who remained endpoint free
Measurement
Patients Measures
Mean value (95% CI) at diagnosis Mean (95% CI) change per year
N N No SE SE P-valuea No SE SE P-valuea
NT-proBNP
(2log pg/mL)
114 637 10.9 (10.5, 11.3) 13.2 (12.5, 13.9) <0.001 1.06 (1.27, 0.85)b 0.26 (0.68, 0.16) 0.001
Length Z-score 137 974 0.67 (0.89, 0.44) 0.18 (0.58, 0.22) 0.040 0.02 (0.08, 0.04) 0.42 (0.56, 0.27)b <0.001
LVIDd Boston
Z-score
136 587 4.5 (3.9, 5.2) 5.4 (4.2, 6.7) 0.221 0.60 (0.82, 0.38)b 0.24 (0.28, 0.75) 0.004
Global peak
strain (%)
112 416 13.3 (12.4, 14.2) 9.8 (7.7, 11.9) 0.003 1.14 (0.75, 1.52)b 0.55 (0.51, 1.62) 0.313
6MWD% (%) 57 277 73.0 (67.0, 79.0) 50.7 (39.6, 61.7) 0.001 0.23 (0.92, 0.45) 0.22 (1.47, 1.90) 0.627
NYU PHFI 133 844 7.8 (7.1, 8.6) 10.6 (9.2, 11.9) <0.001 1.16 (1.41, 0.91)b 0.49 (0.13, 1.10) <0.001
CI, confidence interval; LVIDd, left ventricular internal diastolic dimension; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYU
PHFI, New York University Pediatric Heart Failure Index; SE, study endpoint.
Results are derived from linear mixed-effects model with risk factor as dependent variable and time, classification (SE vs. still diseased),
and time × classification as independent variables.
aP-value for the difference between patients who reached the composite SE of all-cause death or heart transplantation and those who
survived (without transplantation).
bThe slope is significantly (P-value <0.05) different from 0.
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Risk factors for death or heart transplantation
Factors that were associated with an increased risk of death
or HTx included age older than 6 years at diagnosis and at
any time during follow-up: NT-proBNP, LVIDd Z-score, GLS,
6MWD%, and NYU PHFI (Table 4). In multivariable analyses,
NT-proBNP remained the only independent risk factor for
reaching an SE.
Discussion
In this study, we found that the temporal evolution of four
risk factors distinguished the children who died or underwent
transplantation from those who had ongoing disease or who
recovered: no decrease in NT-proBNP or LVIDd, a severe de-
crease in length Z-score, and an increase in NYU PHFI.
Similarly, when comparing children who reached an endpoint
with children with ongoing disease solely, excluding those
who recovered, we found comparable differences in the evo-
lution of risk factors, although the effect size was smaller. In
the multivariate analysis, NT-proBNP remained the only inde-
pendent risk factor for adverse outcome.
We performed two analyses and excluded the children
who recover in the secondary analysis because, in general,
children who recover tend do clinically well at a relatively
early stage after diagnosis. The clinical challenge is to iden-
tify those children who are at the highest risk for adverse
outcome and should be considered for HTx. In this study,
FIGURE 1 Serial measurement of risk factors: N-terminal pro-B-type natriuretic peptide (NT-proBNP) (2log pg/mL), length Z-score, left ventricular in-
ternal diastolic dimension (LVIDd) Boston Z-score, global longitudinal strain (%), 6MWD% (%), and New York University Pediatric Heart Failure Index
(NYU PHFI). The average estimates of the longitudinal trajectory risk factors: the black line indicates the patients without a study endpoint and the
red line the patients with a study endpoint. The dashed lines depict the 95% confidence interval. The coloured lines show the individual patients with
a study endpoint.
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23% of the children, who newly presented, recovered and
median time from diagnosis to recovery was 0.6 years and
confirmed that recovery tends to be an early event.1,3 This
is the first study to our knowledge to analyse this subgroup
of children who remain ill but do not reach the SE. The
finding that the previously mentioned risk factors also dis-
cern these children from those who reached an SE supports
outpatient management and the decision to suspend listing
for HTx.
In the adult counterpart of paediatric DCM, non-ischaemic
cardiomyopathy, studies of risk factors for outcome have fo-
cused on the prevention of sudden cardiac death.15 However,
in children with DCM, the risk of sudden cardiac death is con-
siderably lower than in adults, and most children die or un-
dergo HTx because of pump failure.16 Studies on risk factors
for adverse outcome in adult non-ischaemic heart failure
secondary to pump failure are, therefore, potentially better
comparable with the results of the paediatric studies. In par-
allel with the risk factors we noted in paediatric DCM, natri-
uretic peptides, including NT-proBNP, have been shown
robust prognostic markers for outcome in adult heart failure,
including also in the non-ischaemic subgroup.17–19 Longitudi-
nal strain on CMR imaging has been shown to have incre-
mental predictive value for adverse events in addition to
late gadolinium enhancement and indexed LV end-diastolic
volume.20 In contrast, LV dimension has not been identified
as a solid marker for adverse events.21 However, in patients
demonstrating reverse remodelling, LV dimensions at pre-
sentation were lower and significantly decreased over
time.22 The 6 min walking test at presentation and the
change during follow-up have been associated with heart
failure outcome.23 However, the application of the test in
adults has been limited but may be useful in those with se-
vere heart failure.24
When comparing the results of the previously mentioned
adult reports with the results of our study, NT-proBNP also
remains a strong predictor of outcome in paediatric DCM.
Even after exclusion of the children who recovered, the
differences in temporal evolution of NT-proBNP remained
significant. In this study, we reported a difference in
NT-proBNP at diagnosis between children who reached the
SE and those who did not. This seems to contradict our pre-
vious publication in which we reported no difference in
NT-proBNP at diagnosis.6 A likely explanation is the steep de-
cline of NT-proBNP in children without the SE in the first
30 days after diagnosis, as shown by den Boer et al.6 In this
study, we analysed the data in one time frame, and the linear
model underestimated NT-proBNP at diagnosis. We could
confirm this as median NT-proBNP at diagnosis was not
different in standard statistical tests (Table 1). Our results fur-
ther corroborate the association of NT-proBNP and outcome
in children and adults with heart failure.6,17,25–27 Whether the
evolution of NT-proBNP truly is the only predictor of outcome
or whether the other risk factors also hold independent pre-
dictive information remains to be studied in a larger cohort or
with longer follow-up. Moreover, our findings apply to the
midterm outcome with a median time after diagnosis to last
follow-up of 3.5 years.
Although in the multivariate analysis all risk factors but
NT-pro BNP lost their association with the SE, the temporal
evolution of the other three risk factors still holds important
information. First, LVIDd in children who reached an endpoint
did not change over time in contrast to children not reaching
an endpoint where LVIDd decreased, even after exclusion of
children who recovered (Tables 2 and 3). Temporal evolution
of GLS cannot be used to predict outcome because the slopes
are not different in the two analyses. However, GLS at the
time of diagnosis still might be useful. In the model, the
Table 3 Differences in risk factors between patients who reached the study endpoint of all-cause death or heart transplantation and
those who survived (without transplantation) but remained diseased
Measurement
Patients Measures
Mean value (95% CI) at diagnosis Mean (95% CI) change per year
N N Still diseased SE P-valuea Still diseased SE P-valuea
NT-proBNP
(2log pg/mL)
93 521 10.8 (10.3, 11.4) 13.2 (12.5, 14.0) <0.001 0.41 (0.49, 0.33)b 0.19 (0.38, 0.01)b 0.037
Length Z-score 114 638 0.67 (0.95, 0.39) 0.20 (0.63, 0.23) 0.076 0.04 (0.06, 0.01)b 0.29 (0.37, 0.22)b <0.001
LVIDd Boston
Z-score
113 467 5.2 (4.5, 6.0) 5.6 (4.4, 6.8) 0.618 0.23 (0.33, 0.12)b 0.14 (0.11, 0.39) 0.010
Global peak
strain (%)
89 299 13.0 (11.9, 14.1) 9.0 (7.0, 11.1) 0.001 0.42 (0.24, 0.60)b 0.43 (0.04, 0.91) 0.948
6MWD% (%) 53 262 74.1 (67.6, 80.6) 50.7 (39.6, 61.8) 0.001 0.34 (1.05, 0.37) 0.20 (1.49, 1.90) 0.560
NYU PHFI 110 672 8.45 (7.5, 9.2) 10.6 (9.2, 11.9) 0.006 0.49 (0.60, 0.38)b 0.36 (0.07, 0.66)b <0.001
CI, confidence interval; LVIDd, left ventricular internal diastolic dimension; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYU
PHFI, New York University Pediatric Heart Failure Index; SE, study endpoint.
Results are derived from linear mixed-effects model with risk factor as dependent variable and time, classification (SE vs. still diseased),
and time × classification as independent variables.
aP-value for the difference between patients who reached the composite SE of all-cause death or heart transplantation (‘SE’) and those
who survived (without transplantation) but remained diseased (‘still diseased’).
bThe slope is significantly (P-value <0.05) different from 0.
6 M. van der Meulen et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13233
intercepts of GLS were significantly different between the
two groups (Tables 2 and 3), suggesting that early after pre-
sentation, it may be an indicator for outcome. That observa-
tion is compatible with our previous report that lower GLS
was associated with an increased risk of death or HTx in a
cross-sectional sample and similar to observations in adults
with chronic heart failure.8,28 The second and third risk fac-
tors specifically pertain to the paediatric population: length
Z-score and a paediatric heart failure score (NYU PHFI).
Length growth is considered a solid proxy for overall health
in children and provides a long-term reflection of disease se-
verity. The development of length Z-score distinguished
children who reached an endpoint from those with ongoing
disease (Table 3). In clinical practice, length growth virtually
ceased in children reaching an endpoint. Similarly, Alvarez
et al. reported that small height for age was associated with
a risk of death, but not for being listed for transplantation,
also suggesting that length growth may be a useful indicator
for disease severity in these children.3 Previously, we re-
ported that NYU PHFI independently predicted death and
HTx in children with DCM in a cross-sectional sample.29
Now we have demonstrated that children who reach the SE
were characterized by an increase in NYU PHFI opposed to
those with ongoing disease.
FIGURE 2 Serial measurement of risk factors: N-terminal pro-B-type natriuretic peptide (NT-proBNP) (2log pg/mL), length Z-score, left ventricular in-
ternal diastolic dimension (LVIDd) Boston Z-score, global longitudinal strain (%), 6MWD% (%), and New York University Pediatric Heart Failure Index
(NYU PHFI). The average estimates of the longitudinal trajectory risk factors: the black line indicates the patients with ongoing disease and the red
line the patients with a study endpoint. The dashed lines depict the 95% confidence interval. The coloured lines show the individual patients with
a study endpoint.
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In the light of the interpretation and generalization of our
findings, it is important that after the first year after diagno-
sis, the (transplant-free) survival curves of the Pediatric
Cardiomyopathy Registry and the National Australian Child-
hood Cardiomyopathy Study are similar to ours.1,2 We have
previously reported a low HTx rate in children with DCM in
the first year after diagnosis, without an increase in
mortality.5 The data presented in this study confirm that find-
ing and support the idea that a low early HTx rate does not
lead to an increase in mortality or Htx rate in the years fol-
lowing diagnosis as a result of postponing HTx. This implies
that the children with DCM in both cohorts are comparable
in disease severity. The results we found would therefore
be applicable in other populations of children with DCM, af-
ter the first year after diagnosis.
Although we are unable to calculate a risk score that help
us to select children for listing for transplantation, from our
data, three groups with distinguishable profiles emerge: one
group with a high likelihood of recovery, one group with a
low likelihood of (early) recovery, but a low risk of adverse
outcome, and, finally, one group with a high risk of adverse
events. In our programme, children are listed for transplanta-
tion early after presentation if they cannot be weaned
off inotropes after multiple attempts or are sliding on
inotropes and/or require ventricular assist device support.5
If discharged, oral heart failure therapy is optimized and the
decision to list for transplantation is individualized, but often
postponed until (renewed) admission for inotropic and/or
ventricular assist device support is necessary. Children with
a high-risk profile are monitored closely. In all others, 3 month
interval follow-up is planned and persistent and/or progres-
sive increments in NT-proBNP are considered warning signs
of deterioration and are used to monitor these children as
high risk.
Study limitations
This study has limitations. First, our study cohort is a combi-
nation of two cohorts and consists of children with a prior di-
agnosis before inclusion in this study, as well as children who
are included directly after diagnosis. This may have induced a
selection bias. However, the outcome of the cohort of newly
diagnosed children that we included (Supporting Information,
Figure S1) is the same as the outcome of the children that we
previously reported that presented between 2005 and 2010,
indicating that the large majority of children that we included
with a prior diagnosis were obtained from a cohort with the
same characteristics.5 Second, the primary aim of our study
was to evaluate the prognostic value of the temporal evolu-
tion of (previously identified) risk factors in children with
DCM. Therefore, we did not include a control group of
children without DCM, and hence, our study was not suited
to evaluate hypotheses with respect to such subjects.
Table 4 Risk factors for the composite study endpoint of death or heart transplantation
No. of patients No. of repeated observations No. of endpoints HR (95% CI) P-value
Age over 6 years 137 — 36 3.97 (1.94, 8.15) <0.001
Idiopathic DCM 137 — 36 0.79 (0.41, 1.55) 0.502
NT-proBNP (2log pg/mL) 114 637 32 2.97 (2.10, 3.81) <0.001
Length Z-score 137 974 36 0.78 (0.58, 1.08) 0.136
LVIDd Boston Z-score 136 587 35 1.27 (1.10, 1.48) <0.001
Global peak strain (%) 112 416 22 0.35 (0.16, 0.62) <0.001
6MWD% (%) 57 277 14 0.90 (0.87, 0.94) <0.001
NYU PHFIa 133 844 33 3.31 (2.41, 4.74) <0.001
Age over 6 years 114 637 32 3.16 (0.82, 13.4) 0.078
NT-proBNP (2log pg/mL) 2.95 (2.16, 3.87) <0.001
Idiopathic DCM 114 637 32 1.85 (0.43, 12.1) 0.374
NT-proBNP (2log pg/mL) 2.98 (1.55, 3.91) <0.001
Length Z-score 114 638 32 1.09 (0.63, 1.90) 0.751
NT-proBNP (2log pg/mL) 7.31 (3.99, 13.4) <0.001
LVIDd Boston Z-score 114 638 32 0.91 (0.74, 1.11) 0.334
NT-proBNP (2log pg/mL) 8.35 (4.26, 16.4) <0.001
Global peak strain (%) 97 579 19 0.89 (0.74, 1.08) 0.233
NT-proBNP (2log pg/mL) 8.50 (3.27, 22.1) <0.001
6MWD% (%) 46 308 13 0.95 (0.89, 1.01) 0.088
NT-proBNP (2log pg/mL) 5.24 (1.57, 17.5) 0.007
NYU PHFIa 107 536 29 0.83 (0.24, 2.84) 0.766
NT-proBNP (2log pg/mL) 11.0 (3.30, 36.4) <0.001
CI, confidence interval; DCM, dilated cardiomyopathy; HR, hazard ratio; LVIDd, left ventricular internal diastolic dimension; NT-proBNP, N-
terminal pro-B-type natriuretic peptide; NYU PHFI, New York University Pediatric Heart Failure Index.
aAfter Box–Cox transformation (λ = 0.75).
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Noteworthy, in this respect, the design of our study is similar
to numerous other studies on variables carrying prognostic in-
formation in paediatric and adult heart failure.1,30,31 Third,
missing data were an issue, as may be expected in a longitudi-
nal multicentre study in children. NT-proBNP measurements
were available in all centres except one, where BNP measure-
ments were reported. Furthermore, strain analyses could not
be obtained from the data sets available on all echo machines
throughout the course of the study. The 6MWD% could only
be obtained in outpatient children older than 6 years, but
not in those hospitalized at the ICU. Fourth, the number of
endpoints was limited, which may have hampered the power
of our analyses. However, we still found robust significances
for most of the regression and univariate analyses with the
data that were available. Furthermore, the multivariate analy-
sis was likely affected by the limited number of endpoints. In-
spection of the results of the multivariate analysis suggests
that the missing data for NT-proBNP and the strain analyses
were not the critical factor. Lastly, the decision to list a patient
for HTx is based onmultiple clinical factors. It could be that the
reported risk factors predict decision making by clinicians
rather than outcome. However, the children that underwent
HTx were in such a condition that they most likely would have
died otherwise.32
Conclusions
In summary, we conclude that in children with DCM,
change over time in known risk factors for death or HTx
is predictive for outcome. In children who do not recover,
persistent high levels of NT-proBNP, no decrease in LVIDd,
severe stunting of growth, and an increase in the heart fail-
ure score identify those at the highest risk for death or HTx.
In this study, with a limited number of SEs, we identified
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